Correction

In our article *Indacaterol for COPD* (DTB 2011; 50: 58-60) we included the statement: "This recommends a short-acting inhaled bronchodilator (either a beta₂ agonist or short-acting muscarinic antagonist) as initial therapy for the relief of breathlessness and for reducing exercise limitation, with the addition of long-acting bronchodilators *and/or* an inhaled corticosteroid for people who remain breathless or have exacerbations." Thank you to commentators who pointed out that it should have read "with the addition of long-acting bronchodilators *and* an inhaled corticosteroid for people who remain breathless or have exacerbations."¹

1. National Clinical Guideline Centre, 2010. *Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE Clinical Guideline 101* [online]. Available: <http://www.nice.org.uk/nicemedia/live/13029/49425/49425.pdf> [Accessed 24 May 2012].

DOI: 10.1136/dtb.2012.06.0108